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Background: A combination of inhaled corticosteroid and long-acting beta2 agonist (ICS/LABA) is used frequently
to treat chronic obstructive pulmonary disease (COPD) patients. The aim of the study was to determine whether
prescribing ICS/LABA to COPD patients in primary care in 2009/10 was within the GOLD guidelines and whether
and to what degree patient characteristics were associated with prescription of these drugs by GPs.
Methods: This was a cross-sectional study in seven Norwegian GP practices. Patients registered with a diagnosis of
asthma or COPD in the previous five years were included.
Results: Among the 376 patients included in the analysis, 149 patients had COPD, defined as a post-bronchodilator
FEV1/FVC <0.7 and 55.6% of these patients were treated with ICS/LABA. The rate of prescribing was significantly
higher in the COPD patients also diagnosed with asthma than in those with COPD as the only diagnosis, 66.7%,
and 39.0%, respectively (P = 0.001). The prescribing rate in the latter subgroup would have been 18.6% if the 2007
GOLD guidelines had been followed. One or more exacerbations in the previous year was the strongest predictor
of ICS/LABA prescribing in the COPD patients who were not registered with a concomitant diagnosis of asthma
(OR 3.2, 95% CI 1.0–10.0) but this association was limited to the patients with severe disease (FEV1% predicted <50)
(OR 13.5, 95% CI 1.8–101.1). Cardiovascular disease was associated with decreased ICS/LABA prescribing (OR 0.4,
95% CI 0.2–0.8) in the COPD group. A Kappa coefficient of 0.32 was found between the actual prescribing rate and
that recommended in the 2007 GOLD guidelines.
Conclusions: Overprescribing of ICS/LABA for the COPD patients was shown. Previous exacerbation was a strong
predictor of ICS/LABA prescribing only in patients with severe COPD. Because of the low emphasis on previous
exacerbation when prescribing for COPD patients with mild to moderate disease, the actual prescribing rate agreed
more closely with the GOLD guidelines from 2007 than with those published in 2011. Cardiovascular disease was
associated with decreased prescribing, indicating that GPs adjust the treatment in cases with multimorbidity.
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Although smoking cessation remains the most important
treatment of chronic obstructive lung disease (COPD)
[1], there is evidence that pharmacotherapy also is im-
portant for decreasing symptoms and exacerbation [2].
Inhaled corticosteroid (ICS) in combination with long-
acting beta2 agonists (LABAs) is a very successful option
in patients with asthma [3]. Although less efficacious in
COPD patients, ICS/LABA has become a common choice
for COPD patients based on the findings of studies showing* Correspondence: elindr@hotmail.com
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unless otherwise stated.its efficacy in reducing the frequency and severity of ex-
acerbation [2]. The evidence for the usefulness of ICS/
LABA for treating moderate COPD has been limited.
The Global Initiative for Chronic Obstructive Lung
Diseases (GOLD) guidelines between 2007 and 2010
recommended such treatment only for patients with se-
vere COPD, defined as GOLD III–IV, forced expiratory
volume in one second (FEV1) <50% of the predicted
value, and frequent (≥2 yearly) exacerbation [4]. ICS/
LABA is prescribed for most COPD patients in some
countries and to patients with FEV1% predicted ≥50
[5,6]. A more positive attitude towards the use of ICS/
LABA in patients with moderate COPD is reflected inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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should now be considered for mild to moderate COPD
when the patient experiences frequent exacerbations.
The aim of this study was to describe the prescribing
of ICS/LABA to patients with COPD aged 40 years or
more in Norwegian general practice in 2009/2010 and to
determine whether and to what extent the pattern of
prescription corresponded to the GOLD guidelines for
that period. We also wanted to determine to which
degree various patient characteristics were associated
with the prescribing by GPs and, in particular, whether
previous exacerbation could predict ICS/LABA prescribing.
Methods
General practitioners (GPs) from seven Norwegian
practices were asked to participate in the study. Only
practices with an electronic medical record system
compatible with the registration software used were
selected. These practices had 43,241 patients listed, of
whom 18,931 (43.8%) were aged 40 years or older. Of
these, 1,784 (9.4%) had been registered with a diagnosis
of asthma, COPD, or both in the previous five years. A
random sample of these 1,784 patients, following an
alphabetical order, was invited by mail to participate in
the study. The patients gave written informed consent
and were examined during a stable phase of their
disease between April 2009 and March 2010.
Registrations
Asthma and COPD diagnoses, recorded by a GP in the
electronic medical record during the five years before
the examination, were automatically registered by software
developed by Mediata AS, Norway. Comorbidities were
registered by the GPs on a computerized questionnaire
linked to the medical record. The GPs also registered the
medications currently prescribed for obstructive lung
disease. Exacerbation of asthma or COPD treated with
antibiotics and/or oral corticosteroids in the previous
12 months were also recorded. The patients recorded
on a form whether they had been hospitalized for
asthma or COPD in the previous 12 months, follow-up
of their lung disease in secondary care, and their history
of smoking. Symptoms and limitations of daily activities
for the seven days preceding the examination were reg-
istered using the Clinical COPD Questionnaire (CCQ),
yielding scores of 0–6 for 10 items [7]. The patients
also reported the medications they had used the day
before the examination. The patients were instructed
not to take any pulmonary medication on the day of
the examination.
Spirometry
Spirometry was performed by trained health workers fol-
lowing the guidelines from European Respiratory Societyand American Thoracic Society [8], and the Spirare
SPS310 spirometer (Diagnostica AS, Norway) was used
in all practices. The patients were seated, and a nose clip
was not used. Post-bronchodilator spirometry was per-
formed 20 min after inhalation of 0.4 mg salbutamol.
The post-bronchodilator FEV1 and forced vital capacity
(FVC) were used in the analyses. Norwegian reference
values for spirometry were applied [9].
Analysis
Patients with a post-bronchodilator FEV1/FVC ratio <0.7
were classified as having COPD, even though some had
a combination of asthma and COPD [10]. Patients with
spirometry incompatible with COPD according to the
GOLD guidelines (FEV1/FVC ratio ≥0.7), including pa-
tients with a restrictive spirometry pattern (both FEV1%
predicted and FVC% predicted <80) were analysed sep-
arately to compare the COPD patients with other pa-
tients deemed to have obstructive lung disease. In the
analysis, FEV1% predicted was categorized into three
levels: <50%, 50–80% and ≥80%. The CCQ score was
also categorized into three levels: <1, 1–2, and ≥2.
Exacerbation of COPD was defined as in the ECLIPSE
study as follows. “Events that led a care provider to pre-
scribe antibiotics or corticosteroids (or both) or that led
to hospitalization” [5]. One or more episodes of moder-
ate to severe exacerbation [11] during the previous year
were categorized as “exacerbation in the previous year”.
Patients were classified as having cardiovascular disease
if their GP had recorded coronary heart disease, other
heart disease, or stroke. Treatment with both ICS and
LABA was classified as treatment with ICS/LABA re-
gardless of whether the medicine was given in a combin-
ation inhaler or in separate inhalers.
The significance of differences between groups were
analysed by chi-square statistics. Agreement between
actual and recommended prescribing was analysed by
Kappa statistics. The category of exacerbation in the pre-
vious year was used as a proxy for frequent exacerbation
in this analysis. Predictors of prescribing ICS/LABA were
analysed by univariable logistic regression. SPSS 19.0
(IBM Corp., Armonk, NY, USA) was used for the statis-
tical analyses.
The study was approved by the Regional Committee
for Medical and Health Research Ethics.
Results
Patients’ characteristics
Of the random sample of 1,111 invited, 380 (34.2%)
accepted and completed in the examination. Two pa-
tients were excluded from the analysis because of symp-
toms and signs of an ongoing exacerbation, and two
patients were excluded because they had not completed
post-bronchodilator spirometry. Of the 376 remaining
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of COPD only in the previous five years, 210 (55.8%)
with asthma only, and 92 (24.5%) with both diagnoses
(Table 1). Among the 376 patients, 23.7% reported that
their current diagnosis had been given by a secondary
care doctor, and 7.2% that their lung disease was usually
followed up at this level of care.
The median age was 62 years. The mean CCQ score
was 1.68 (SD 0.98) for the 353 patients who answered all
10 CCQ questions. Post-bronchodilator spirometry indi-
cating COPD (FEV1/FVC <0.7) was found in 149 pa-
tients (39.6%) and more frequently among men (48.3%)
than among women (34.3%) (Table 1). Of these 149
patients, 70.5% were classified according to the 2007
GOLD stages with mild to moderate COPD (GOLD I–
II) and 29.5% with severe or very severe COPD (GOLD
III–IV); 39.6% had been given a COPD diagnosis but no
asthma diagnosis by their GP, and 36.2% had been diag-
nosed with both asthma and COPD (Table 1). Exacerba-
tion in the previous year was registered in 54 of the 149
COPD patients (36.2%) and in 19 (32.2%) of the 59Table 1 Patient characteristics and diagnosis registered in the
patients aged ≥40 years diagnosed with an obstructive lung
FEV1/FVC <0.7 (n = 149)
n (%)
Men 69 46.3






COPD only 59 39.6
COPD and asthma 54 36.2
Asthma only 36 24.4
Other illness (GP reported)
Allergic rhinitis and/or eczema 46 30.9
Cardiovascular disease 64 43.0










bData missing for 23 patients.COPD patients with COPD as the only diagnosis regis-
tered. A combination of FEV1% predicted <50 and ex-
acerbation in the previous year, indicating that ICS/
LABA could be prescribed according to the 2007 GOLD
guidelines, was found in 19 (12.6%) of the 149 COPD
patients and in 11 (18.6%) of the 59 COPD patients with
COPD as the only diagnosis.Medication prescribed
Two hundred and ninety-five (78.5%) patients were on
pulmonary medication. ICS/LABA was prescribed to
55.7% of all patients with COPD, and in 94% of these as
a combined inhaler. ICS/LABA was prescribed (in a
combined or separate inhaler) somewhat less frequently
in those with an FEV1/FVC ≥0.7, but the difference was
not significant (Table 2). ICS/LABA was prescribed to
63.6% of the patients with GOLD III–IV severity and to
52.4% of the patients with GOLD I–II (the difference
was not significant). In the COPD group, the patients
who had been diagnosed with asthma were prescribedmedical records for the previous five years in 376
disease in primary care



















Table 2 Medication prescribed and medication taken on the previous day in 376 patients aged ≥40 years diagnosed
with an obstructive lung disease in primary care according to whether COPD was indicated by spirometry
(FEV1/FVC <0.7)
FEV1/FVC <0.7 (n = 149) FEV1/FVC ≥0.7 (n = 227)
Medication Prescribed % Taken the previous day % Prescribed % Taken the previous day %
SABA 42.3 24.8 35.7 19.8
LABA, no ICS 10.7 7.4 4.8 3.1
ICS, no LABA 8.1 6.0 14.5 10.6
ICS/LABA combined 55.7 49.0 46.7 37.4
Anticholinergics 41.6a 38.3a 10.3 5.7
Theophylline 1.3 0.75 1.3 0.9
Montelukast 7.3 5.4 13.2 10.0
Prednisolone 2.0 1.3 0 0.9
Any pulmonary medication 83.2 72.5b 75.3 62.6
aP < 0.001, difference between the two patient groups.
bP = 0.05, difference between the two patient groups.
SABA: short-acting beta2 agonist, LABA: long-acting beta2 agonist, ICS: inhaled corticosteroid.
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who had COPD as the only diagnosis (39.0%) (P < 0.001)
(Figure 1). The Kappa coefficient was 0.37 (SE 0.12)
for the comparison between ICS/LABA prescribed to
the COPD patients without a diagnosis of asthma and
the medication recommended in the 2007 GOLD
guidelines. Overprescribing was much more common
than underprescribing (Table 3). The opposite was the
case when comparing the actual prescribing with the
recommended prescribing based on the 2011 GOLD
guidelines, which produced a lower Kappa coefficient
(Table 4).
Medication taken
Among the patients who took prescribed pulmonary
medication, the great majority had taken prescribed
medication on the previous day (Table 2). Among the
COPD patients who had been prescribed pulmonary
medication, 86.7% had taken ICS/LABA and 88.7% had
taken an anticholinergic on the previous day. The corre-
sponding frequencies among the patients with an FEV1/
FVC ≥0.7 were 80.2% and 56.5%.
Predictors of ICS/LABA prescribing
The strongest predictors of increased ICS/LABA pre-
scribing in the COPD group were an asthma diagnosis
registered by the GP and exacerbation registered in the
previous year (Table 5). The same variables and increased
mean CCQ score were significant predictors in the group
with an FEV1/FVC ≥0.7. Cardiovascular disease was asso-
ciated with a decreased ICS/LABA prescribing in the
COPD group as was current smoking (P = 0.06). When
evaluating the predictors in the 59 COPD patients who had
not received an asthma diagnosis, previous exacerbation
was the only significant predictor (Odds ratio (OR) 3.2,95% confidence interval (CI) 1.0–10.0). When splitting
these 59 patients into two groups according to FEV1% pre-
dicted, <50 and ≥50, previous exacerbation was a signifi-
cant predictor when FEV1% predicted was <50 (OR 13.5,
95% CI 1.8–101.1) but not when FEV1% predicted was ≥50
(OR 0.7, 95% CI 0.1–4.2). Cardiovascular disease had the
same OR (0.4) in the COPD patients without an asthma
diagnosis as in all patients with an FEV1/FVC <0.7, but this
association was not significant (P = 0.08).
Discussion
Main findings
ICS/LABA was the most frequently prescribed drug in
this study and was prescribed to 55.7% of the patients
with COPD (FEV1/FVC <0.7), and the great majority of
these patients had used this combination the day before
the examination. ICS/LABA was prescribed more fre-
quently than recommended in the 2007 GOLD guide-
lines for COPD patients without a concomitant asthma
diagnosis, although a fair agreement between the recom-
mendations and prescribing was found (Kappa = 0.32).
Exacerbation in the previous year was a significant pre-
dictor among the COPD patients without a concomitant
asthma diagnosis. However, this association was signifi-
cant only when FEV1% predicted was <50 in the group
only diagnosed with COPD . This explains why the actual
ICS/LABA prescribing in 2009/10 was more consistent
with the 2007–10 GOLD guidelines than with the later
2011 guidelines [1]. We also identified that concurrent
cardiovascular disease was associated with decreased pre-
scribing of ICS/LABA in COPD patients.
Comparison with previous studies
Similar high prescription rates of ICS/LABA in COPD
patients have been found in previous studies [5,6] and
Figure 1 Frequency of prescribing ICS/LABA to patients with asthma or COPD in primary care according to lung function and diagnosis
registered by GPs.
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LABA is recommended in subgroups of COPD patients,
to our knowledge, no one has described the characteris-
tics of patients who are prescribed this combination by
their GP in real clinical practice. The importance at-
tached to previous exacerbation by the GPs was also
supported by the ECLIPSE study, which showed that
previous exacerbation predicted future exacerbation [5],
and by the TORCH study, which showed that ICS/LABA
reduced the risk of exacerbation [14].
Strengths and weaknesses
A strength of this study is that post-bronchodilator spir-
ometry was performed and that 95.5% of the patients
expired for six seconds or more [15]. Another strength
of the study is the complete information on medication,
symptoms and exacerbation provided by these dedicated
GPs and patients. Although Norwegian GPs are usually
well informed about the treatments given to their pa-
tients in secondary care, some underreporting regarding
prescribed medication and hospitalizations may haveTable 3 Agreement between actual prescribing of ICS/LABA
for 59 COPD patients (FEV1/FVC <0.7) with no concomitant
diagnosis of asthma in 2009/10 and the prescribing
recommended based on the 2007–2010 GOLD guidelines
ICS/LABA recommended




Yes 9 14 23
No 2 34 36
11 48 59
Kappa = 0.37 (SE 0.12)occurred, but probably not in a systematic manner that
would have affected the trends in our study. The inclu-
sion of patients diagnosed with only asthma, only
COPD, and patients with both diagnoses is another
strength and reflects the diagnostic uncertainty in pri-
mary care. Some of the COPD patients with a concomi-
tant asthma diagnosis probably had persistent asthma or
asthma that was not optimally controlled, and some had
a combination of asthma and COPD. Such patients are
usually treated with ICS/LABA. Some of the patients
who were registered as having asthma and who had an
FEV1/FVC <0.7 were probably regular COPD patients.
The shift in diagnostic labelling from asthma to COPD
the past 15 years because of the new awareness of COPD
as a separate diagnosis, is still progressing [15-17]. The
Norwegian reimbursement regulations between 2006 and
2010, which restricted reimbursement of ICS/LABA costs
to patients with asthma only, probably slowed this
process. Because of the improper application of the
asthma diagnosis among the COPD patients, theTable 4 Agreement between actual prescribing of ICS/LABA
for 59 COPD patients (FEV1/FVC < 0.7) with no concomitant
diagnosis of asthma in 2009/10 and the prescribing
recommended based on the 2011 GOLD guidelines
ICS/LABA recommended




Yes 14 9 23
No 17 19 36
31a 28 59
Kappa = 0.13 (SE 0.12)
aFrequent exacerbation only was recorded in eight patients, predicted FEV1%
<50% only in 12 patients, and both findings in 11 patients.
Table 5 Predictors of ICS/LABA prescribing as determined by bivariate logistic regression according to lung function in
376 patients aged ≥40 years diagnosed with an obstructive lung disease in primary care according to whether COPD
is indicated by spirometry (FEV1/FVC <0.7; n = 149) or not (n = 227)
FEV1/FVC <0.7 FEV1/FVC ≥0.7
OR 95% CI P-value OR 95% CI P-value
Age 65+ years 0.8 0.4–1.6 0.6 1.0 0.6–1.8 0.9
Male 0.6 0.4–1.3 0.7 1.0 0.6–1.8 0.9
Never smoker 1 1
Current smoker 0.3 0.1–1.1 0.06 0.7 0.4–1.4 0.3
Previous smoker 0.5 0.1–1.4 0.5 0.7 0.4–1.3 0.3
Diagnosis (by GP)
Asthma 3.1 1.6–6.2 0.001 6.3 1.4–28.4 0.02
COPD 0.5 0.2–1.2 0.1 0.6 0.3–1.2 0.1
Cardiovascular disease 0.4 0.2–0.8 0.01 1.2 0.7–2.2 0.6
Allergic illness 1.5 0.8–3.2 0.2 1.4 0.8–2.4 0.2
Exacerbation in the previous year 2.0 1.0–4.1 0.04 2.3 1.9–4.5 0.01
CCQ mean scorea
<1 1 1
1–2 1.8 0.7–4.5 0.2 1.3 0.7–2.6 0.4
≥2 2.0 0.8–5.0 0.1 2.2 1.1–4.3 0.03
FEV1% predicted
≥50% 1 1
<50% 1.6 0.8–3.3 0.2 2.9 0.6–15.5 0.2
OR = odds ratio, CI = confidence interval.
aData missing for 23 patients.
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has probably been overestimated. A bigger problem in
our analysis was the small size of the subgroup of
patients with definitive COPD diagnosis (FEV1/FVC
<0.7 and COPD as the only diagnosis given by the GP).
We did not register the frequency that patients had
consulted their GP in the previous year. Patients with
exacerbation in the previous year might have had a
higher consulting rate than other patients and, accordingly,
may have been more likely to have ICS/LABA prescribed.
This might have led to an overestimation of previous
exacerbation as predictor of such prescribing. On the other
hand, a reduced exacerbation rate in patients because of
treatment with ICS/LABA for more than 1 year might
have weakened the association between exacerbation in
the previous year and ICS/LABA prescribing.
The GP offices chose to participate in the study volun-
tarily and might not be representative of Norwegian
practices. As shown in a previous paper, this probably
did not affect the diagnostic labelling [15].
Cardiovascular comorbidity and smoking
The GPs seemed to be more reluctant to prescribe ICS/
LABA to COPD patients with cardiovascular comorbidity.
The most recent guidelines have been criticized for notconsidering multimorbidity [18]. There has been too
much emphasis on vertical integration across primary and
secondary care and too little focus on holistic care to
patients with multimorbidity [19]. In this critique
COPD patients have been in focus because of the high
prevalence of cardiovascular disease and depression in
this disease group [20]. In the TORCH study, which
evaluated the usefulness of ICS/LABA treatment in
COPD, patients with cardiovascular comorbidity were
not excluded, and 40% were on cardiovascular drugs
[21]. Treatment with ICS/LABA was not associated
with increased risk of adverse cardiovascular effects. Al-
though cardiovascular comorbidity was not a criterion for
exclusion in the TORCH study, patients likely to die of
causes other than COPD in the coming three years were
not included [21] and, for this reason, some patients with
heart failure were probably excluded. Because ICS/LABA
has not been proven to decrease mortality in COPD
patients, an eagerness to add this medication might
have been outweighed by concern about adverse effects
and polypharmacy.
Current smoking was associated with decreased ICS/
LABA prescribing among the COPD patients, although
this finding was not significant and must be interpreted
with caution. It is possible that some GPs postpone
Drivenes et al. BMC Family Practice 2014, 15:42 Page 7 of 7
http://www.biomedcentral.com/1471-2296/15/42giving ICS/LABA treatment to smoking patients to
maintain a strong focus on the most important measure
for the patient, smoking cessation. GPs may wish to
emphasize the patient’s responsibility for managing the
medical condition and its future course.
ICS/LABA for COPD in the future
The efficacy of ICS/LABA in COPD patients has been
questioned in a recent Cochrane analysis [22,23], and
discontinuation of such therapy in selected COPD pa-
tients has been shown to be safe [17,23]. Efforts to classify
COPD patients into phenotypes may help ensure a more
optimal use of ICS/LABA as maintenance treatment in
COPD patients [24].
Conclusion
Compared with the 2007 GOLD guidelines, ICS/LABA
was overprescribed. The GPs seemed to emphasize pre-
vious exacerbation as a rationale in their prescribing but
mainly for patients with severe COPD. The GPs were
somewhat reluctant to prescribe ICS/LABA to COPD
patients with cardiovascular comorbidity, possibly to avoid
unnecessary adverse effects and polypharmacy.
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